HUTCHMED (China) Ltd. has announced advances in its research and development pipeline during its recent R&D Updates event. The company unveiled its next-generation Antibody-Targeted Therapy Conjugate (ATTC) platform, highlighting its potential to provide precision oncology solutions through a dual-mechanism of action. The lead candidate, HMPL-A251, utilizes a selective PI3K/PIKK inhibitor payload and has shown promising preclinical efficacy and safety in HER2-positive and HER2-low models, both with and without PAM alterations. HUTCHMED plans to initiate clinical development of HMPL-A251 starting in late 2025, with initial studies set to evaluate the candidate across various cancer types. These research results were presented during the October 31, 2025 event.